NCT05507541 2026-04-22
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
Phase 2 Active not recruiting
Clinical Trials
1,231 trialsNCT05583708 2026-04-22
iPRRT
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT06027268 2026-04-22
ToPCourT
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT06308913 2026-04-22
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
University of Wisconsin, Madison
Phase EARLY_PHASE1 Active not recruiting
NCT07343596 2026-04-22
Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery
University of Wisconsin, Madison
Phase NA Recruiting
NCT02600949 2026-04-21
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT02957968 2026-04-21
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
Phase 2 Active not recruiting
NCT03149029 2026-04-21
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04946370 2026-04-21
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1/2 Recruiting
NCT03366844 2026-04-20
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
Cedars-Sinai Medical Center
Phase 1/2 Active not recruiting
NCT04393350 2026-04-20
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
Phase 2 Active not recruiting
NCT05491226 2026-04-20
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT05852223 2026-04-20
NePenThe
Istituti Clinici Scientifici Maugeri SpA
Phase 2 Recruiting
NCT06134375 2026-04-20
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Dartmouth-Hitchcock Medical Center
Phase 1/2 Recruiting
NCT07015853 2026-04-20
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Cedars-Sinai Medical Center
Phase 2 Not yet recruiting
NCT02287428 2026-04-17
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04134325 2026-04-17
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04638582 2026-04-17
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Terminated
NCT05119296 2026-04-17
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Phase 2 Active not recruiting
NCT05197322 2026-04-17
NEOPRISM-CRC
University College, London
Phase 2 Recruiting
NCT05766371 2026-04-17
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT06492759 2026-04-17
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Emory University
Phase 2 Recruiting
NCT07283731 2026-04-17
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07523763 2026-04-17
NIVO1002024
Blokhin's Russian Cancer Research Center
Phase 2 Active not recruiting
NCT03435952 2026-04-16
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03618550 2026-04-16
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03634241 2026-04-16
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05064280 2026-04-16
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05967182 2026-04-16
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06545682 2026-04-16
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT04659811 2026-04-15
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
University of California, San Francisco
Phase 2 Active not recruiting
NCT05355051 2026-04-15
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05922904 2026-04-15
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06066333 2026-04-15
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06669572 2026-04-15
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
Phase 2 Recruiting
NCT07172256 2026-04-15
CUE-101with Pembrolizumab for LA-HPV+HNSCCs
Yale University
Phase 2 Not yet recruiting
NCT07213934 2026-04-15
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 1/2 Recruiting
NCT07455032 2026-04-15
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
Fox Chase Cancer Center
Phase 1 Recruiting
NCT05232851 2026-04-14
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
Mayo Clinic
Phase 1/2 Active not recruiting
NCT04520711 2026-04-13
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Providence Health & Services
Phase 1 Active not recruiting
NCT05239624 2026-04-13
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05913388 2026-04-13
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Providence Health & Services
Phase 2 Recruiting
NCT05969496 2026-04-13
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT02819752 2026-04-09
PEACH
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT03236935 2026-04-09
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
Phase 1 Completed
NCT03277638 2026-04-09
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
Case Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT04745988 2026-04-09
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT04938609 2026-04-09
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
Providence Health & Services
Phase 2 Active not recruiting